VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Up 485.2% in September

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 221,800 shares, an increase of 485.2% from the August 31st total of 37,900 shares. Based on an average daily volume of 312,000 shares, the short-interest ratio is presently 0.7 days. Approximately 8.6% of the company’s shares are sold short. Approximately 8.6% of the company’s shares are sold short. Based on an average daily volume of 312,000 shares, the short-interest ratio is presently 0.7 days.

VivoSim Labs Price Performance

NASDAQ:VIVS opened at $2.92 on Wednesday. The company has a fifty day moving average of $2.54. The firm has a market cap of $7.59 million, a price-to-earnings ratio of -0.29 and a beta of 1.11. VivoSim Labs has a 1-year low of $1.41 and a 1-year high of $21.96.

VivoSim Labs (NASDAQ:VIVS) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) EPS for the quarter. The firm had revenue of $0.04 million for the quarter. VivoSim Labs had a negative net margin of 1,396.48% and a negative return on equity of 32.95%.

About VivoSim Labs

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.